Table 1. Demographics of patients in the model study populations.
| ERASMOS (n = 60) |
PMP/NECC (n = 119*) | p-value | |
|---|---|---|---|
| Age, years, median (SD)† | 57 (9.8) | 56 (7.1) | 0.44 |
| CA-125, units/ml, median (SD) † | 155 (689.8) | 88.1 (1335.5) | 0.72 |
| Histology, n (%)‡ | |||
| Control | 0 (0) | 15 (12.6) | <0.0001 |
| Serous cystadenoma/cystadenofibroma | 7 (11.7) | 14 (11.8) | |
| Endometrioma | 0 (0) | 15 (12.6) | |
| Other benign lesion | 9 (15.0) | 0 (0) | |
| Borderline mucinous tumor | 2 (3.3) | 0 (0) | |
| Borderline serous tumor | 5 (8.3) | 15 (12.6) | |
| Stage I/II serous adenocarcinoma | 5 (8.3) | 20 (16.8) | |
| Stage III/IV serous adenocarcinoma | 19 (31.2) | 10 (8.4) | |
| Stage I/II clear cell/endometrioid adenocarcinoma | 6 (10.0) | 20 (16.8) | |
| Stage III/IV clear cell/endometrioid adenocarcinoma | 0 (0) | 10 (8.4) | |
| Mucinous adenocarcinoma | 1 (1.7) | 0 (0) | |
| Other ovarian cancer | 10 (10.0) | 0 (0) | |
| Stage, n (%)‡ | |||
| Not applicable | 16 (26.7) | 59 (49.6) | <0.0001 |
| I | 9 (15.0) | 22 (18.5) | |
| II | 8 (13.3) | 18 (15.1) | |
| III | 19 (31.2) | 18 (15.1) | |
| IV | 8 (13.3) | 2 (1.7) | |
| Grade, n (%)‡ | |||
| Not applicable | 16 (26.7) | 44 (37.0) | 0.07 |
| Borderline | 7 (11.7) | 15 (12.6) | |
| 1 (well-differentiated) | 6 (10.0) | 12 (10.1) | |
| 2 (moderately differentiated) | 3 (5.0) | 12 (10.1) | |
| 3 (poorly differentiated) | 28 (46.7) | 36 (30.3) |
ERASMOS – Effects of Regional Analgesia on Serum miRNA after Oncology Surgery Study.
PMP – Pelvic Mass Protocol.
NECC – New England Case Control study.
*15samples from NECC, 114 samples from PMP.
†student’s t-test.
‡chi-square test.